Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma

doi:10.5306/wjco.v16.i8.109419

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (24)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-3)

Sum=24

Aug 24, 2025 (publication date) through Aug 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Aug 24, 2025; 16(8): 109419
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.109419

Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma

Hu-Yu Jiao, Xin-Mei Yan, Jun-Xin Li, Zhen-Gang Zhang

Hu-Yu Jiao, Xin-Mei Yan, Jun-Xin Li, Zhen-Gang Zhang, Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China

Author contributions: Jiao HY, Yan XM, and Li JX designed the study, collected and analyzed the data, and drafted the manuscript; Zhang ZG designed and revised the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.

Institutional review board statement: This study was approved by the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, approval No. TJ-IRB202412142.

Informed consent statement: This study only analyzed the data and was exempted from informed consent from the patients.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: The datasets used and analyzed in the current study are available from the corresponding author on reasonable request.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Zhen-Gang Zhang, MD, PhD, Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430000, Hubei Province, China. zgzhang@tjh.tjmu.edu.cn

Received: May 12, 2025
Revised: May 25, 2025
Accepted: July 2, 2025
Published online: August 24, 2025
Processing time: 102 Days and 1.3 Hours

Core Tip

Core Tip: This study demonstrates that combining transarterial chemoembolization (TACE) with programmed cell death (ligand) 1 inhibitors and molecular targeted therapy significantly reduces TACE resistance and improves survival in advanced hepatocellular carcinoma. The combination therapy prolongs progression-free survival and overall survival. Additionally, the study identifies maximum tumor diameter, tumor capsule integrity, and bilobar distribution of tumor as key factors influencing TACE resistance, providing new insights for optimizing treatment strategies.